Share

February 2019; 5 (1) Clinical/Scientific NotesOpen Access

Variable reporting of C9orf72 and a high rate of uncertain results in ALS genetic testing

Holly Klepek, Stephen A. Goutman, Adam Quick, Stephen J. Kolb, Jennifer Roggenbuck
First published January 7, 2019, DOI: https://doi.org/10.1212/NXG.0000000000000301
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
673

Share

Article Information

vol. 5 no. 1 e301
DOI: 
https://doi.org/10.1212/NXG.0000000000000301
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2376-7839
History: 
  • Received June 27, 2018
  • Accepted in final form November 2, 2018
  • First Published January 7, 2019.
Copyright & Usage: 
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Holly Klepek, MS,
    2. Stephen A. Goutman, MD,
    3. Adam Quick, MD,
    4. Stephen J. Kolb, MD, PhD and
    5. Jennifer Roggenbuck, MS, CGC
  1. Holly Klepek, MS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stephen A. Goutman, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Cytokinetics

    Research Support, Government Entities:

    1. (1) NIH/NIEHS, K23ES027221, PI, 2017-present (2) CDC/ATSDR, Contract # 200-2013-56856, Co- Investigator, 2013-2017 (3) CDC/ATSDR, R01 TS000289-01, Co-Investigator, 2018-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Target ALS (2) ALS Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Adam Quick, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Stephen J. Kolb, MD, PhD and
    5. Scientific Advisory Boards:

    1. Genentech - Scientific Advisory Meeting

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH: U24NS107205 ? NINDS: ?Network for Excellence in Neuroscience Clinical Trials Center at The Ohio State University? Role: PI, 7/18 ? 6/23 NIH: R01HD060586 ? NICHHD: ?Biomarkers and additive therapies to enhance symptomatic treatment of spinal muscular atrophy? Role: co-PI, 4/17 ? 3/22

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Jennifer Roggenbuck, MS, CGC
    6. Scientific Advisory Boards:

    1. 1) Commercial entity: served on advisory board of Invitae Corp. Was paid $1000 and travel to board meeting paid, 2017.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (H.K.), Indiana University Medical Center, Indianapolis; Department of Neurology (S.A.G.), University of Michigan Medical Center, Ann Arbor; Department of Neurology (A.Q., S.J.K., J.R.) and Department of Biological Chemistry & Pharmacy (S.J.K.), The Ohio State University Wexner Medical Center, Columbus.
  1. Correspondence
    Ms. Roggenbuck jennifer.roggenbuck{at}osumc.edu
View Full Text

Article usage

Article usage: January 2019 to February 2023

AbstractFullPdfSource
Jan 20192259360Highwire
Feb 20191350558Highwire
Mar 20191833737Highwire
Apr 20191630425Highwire
May 20191417824Highwire
Jun 20191622722Highwire
Jul 2019638120Highwire
Aug 2019772612Highwire
Sep 2019471016Highwire
Oct 20191060019Highwire
Nov 2019842418Highwire
Dec 2019824421Highwire
Jan 20204419Highwire
Feb 20200569Highwire
Mar 202024713Highwire
Apr 20202474Highwire
May 202018810Highwire
Jun 20202458Highwire
Jul 20201528Highwire
Aug 20201509Highwire
Sep 202038010Highwire
Oct 20203879Highwire
Nov 202035620Highwire
Dec 20205557Highwire
Jan 202104410Highwire
Feb 20211608Highwire
Mar 202123917Highwire
Apr 20215417Highwire
May 20213382Highwire
Jun 20211285Highwire
Jul 20211617Highwire
Aug 20211686Highwire
Sep 20212404Highwire
Oct 202134124Highwire
Nov 202111313Highwire
Dec 20212204Highwire
Jan 20221427Highwire
Feb 20222276Highwire
Mar 20221164Highwire
Apr 20221245Highwire
May 202202911Highwire
Jun 20222225Highwire
Jul 202231365Highwire
Aug 20221545Highwire
Sep 202215513Highwire
Oct 202246513Highwire
Nov 202229426Highwire
Dec 20220433Highwire
Jan 202316011Highwire
Feb 20230394Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles